Genomic and Circulating Predictors of PAH response

PAH 反应的基因组和循环预测因子

基本信息

  • 批准号:
    9926307
  • 负责人:
  • 金额:
    $ 62.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-05-15 至 2023-04-30
  • 项目状态:
    已结题

项目摘要

SUMMARY Pulmonary arterial hypertension is a relentless disease characterized by vascular obliteration, right heart failure and death. Although there are ten FDA-approved therapies in three classes for PAH, none is curative and approximately 40% of patients are dead within 5 years of diagnosis. There is no established approach to identify patients who will respond to a specific therapy and many patients worsen while waiting for an effective therapy. The goals of this proposal are to improve outcomes in PAH using the concepts of precision medicine through an advanced genetics and “Omics” approach incorporating transcriptomics, proteomics and metabolomics. Within cohorts of unselected PAH patients, there are two subsets with striking responses to therapy. One is a small subset that has a marked reduction in pulmonary artery pressure acutely in response to vasodilators and a dramatic long-term clinical response to calcium channel blocker therapy. We have recently published peripheral blood transcriptomic and genomic signatures of calcium channel blocker responsive patients differentiating them from non-responsive patients. The second subset is patients that have marked improvement with parenteral prostacyclin therapy. We and others have reported normalization of pulmonary arterial pressure in a subset of PAH patients treated with parenteral prostacyclin therapy. In preliminary data, we have identified clinical predictors of long-term survival in response to parenteral prostacyclin therapy and have found transcriptomic patterns that differentiate these patients. We have also identified variability in expression of the prostacyclin receptor in lymphoblastoids of control individuals and suppression of the receptor in PAH. We have preliminarily identified genetic variants that regulate prostacyclin receptor expression and that differentiate patients with good and poor responses to prostacyclin therapy. These data form the basis of our hypothesis that peripheral blood-derived genetic and Omic profiles identify correlates of prostacyclin responsiveness in PAH and can be exploited to understand mechanisms of drug efficacy and to optimize patient care. In this grant we propose to 1) understand genetic variation contributing to differential clinical response to prostacyclin therapy in PAH, 2) identify peripheral blood-derived Omic profiles to identify patients with durable clinical responses to parenteral prostacyclin therapy, 3) prospectively test our genetic and Omic profiles capacity to predict short-term responses to prostacyclin therapy in PAH clinically treated with PPs. The long term goals of this proposal are to better match a patient's unique biology to PP therapy, potentially improving survival in this highly morbid disease.
总结 肺动脉高压是一种以血管闭塞为特征的无情疾病,对吧 心力衰竭和死亡。虽然有10种FDA批准的PAH治疗方法分为三类, 没有一个是治愈性的,大约40%的患者在诊断后5年内死亡。没有 确定对特定治疗有反应的患者的既定方法, 在等待有效治疗的同时恶化。该提案的目标是改善以下方面的成果: PAH通过先进的遗传学和“组学”方法使用精准医学概念 整合了转录组学、蛋白质组学和代谢组学。在PAH队列中 患者中,有两个子集对治疗有显著反应。一个是一个小的子集, 对血管扩张剂的反应是肺动脉压急剧下降, 对钙通道阻滞剂治疗的长期临床反应。我们最近出版了 钙通道阻滞剂反应性的外周血转录组和基因组特征 将其与无反应的患者区分开来。第二个子集是患有 胃肠外前列环素治疗后有显著改善。我们和其他人报告说 接受胃肠外药物治疗的PAH患者亚组的肺动脉压正常化 前列环素治疗在初步数据中,我们已经确定了长期生存的临床预测因素, 对胃肠外前列环素治疗的反应,并已发现转录组模式, 这些病人。我们还发现了前列环素受体在前列腺增生中表达的变异性。 对照个体的淋巴母细胞样瘤和PAH中受体的抑制。我们初步 确定了调节前列环素受体表达的遗传变异, 对前列环素治疗的反应有好有差。这些数据构成了我们假设的基础 外周血来源的遗传和Omic特征识别前列环素的相关性, PAH的反应性,并可用于了解药物疗效的机制, 优化患者护理。在这项资助中,我们建议1)了解遗传变异有助于 PAH患者对前列环素治疗的不同临床反应,2)确定外周血来源的Omic 用于识别对胃肠外前列环素治疗具有持久临床应答的患者的特征,3) 前瞻性地测试我们的遗传和Omic特征预测短期反应的能力, 前列环素治疗临床上接受PP治疗的PAH。该提案的长期目标是 更好地将患者的独特生物学与PP治疗相匹配,可能提高这种高度依赖性的患者的生存率。 病态的疾病

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Anna R Hemnes其他文献

Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients
肺动脉高压未来治疗模式:来自医生、卫生当局和患者的个人观点
  • DOI:
    10.1016/s2213-2600(24)00425-9
  • 发表时间:
    2025-04-01
  • 期刊:
  • 影响因子:
    32.800
  • 作者:
    Franck F Rahaghi;Marc Humbert;Marius M Hoeper;R James White;Robert P Frantz;Paul M Hassoun;Anna R Hemnes;Steven M Kawut;Vallerie V McLaughlin;Gergely Meszaros;Peter G M Mol;Steven D Nathan;Mitchel A Psotka;Farbod N Rahaghi;Olivier Sitbon;Norman Stockbridge;Jason Weatherald;Faiez Zannad;Sandeep Sahay
  • 通讯作者:
    Sandeep Sahay

Anna R Hemnes的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Anna R Hemnes', 18)}}的其他基金

FLI1 in Pulmonary Arterial Hypertension
FLI1 在肺动脉高压中的作用
  • 批准号:
    10727278
  • 财政年份:
    2023
  • 资助金额:
    $ 62.21万
  • 项目类别:
2023 Grover Conference
2023 格罗弗会议
  • 批准号:
    10753743
  • 财政年份:
    2023
  • 资助金额:
    $ 62.21万
  • 项目类别:
Mentorship in Pulmonary Vascular Disease
肺血管疾病的指导
  • 批准号:
    10370102
  • 财政年份:
    2022
  • 资助金额:
    $ 62.21万
  • 项目类别:
Mentorship in Pulmonary Vascular Disease
肺血管疾病的指导
  • 批准号:
    10542767
  • 财政年份:
    2022
  • 资助金额:
    $ 62.21万
  • 项目类别:
Genomic and Circulating Predictors of PAH response
PAH 反应的基因组和循环预测因子
  • 批准号:
    10166908
  • 财政年份:
    2019
  • 资助金额:
    $ 62.21万
  • 项目类别:
Genomic and Circulating Predictors of PAH response
PAH 反应的基因组和循环预测因子
  • 批准号:
    10402363
  • 财政年份:
    2019
  • 资助金额:
    $ 62.21万
  • 项目类别:
Genomic and Circulating Predictors of PAH response
PAH 反应的基因组和循环预测因子
  • 批准号:
    10393072
  • 财政年份:
    2019
  • 资助金额:
    $ 62.21万
  • 项目类别:
Lipid Deposition in the Right Ventricle in Pulmonary Arterial Hypertension
肺动脉高压右心室脂质沉积
  • 批准号:
    9197665
  • 财政年份:
    2015
  • 资助金额:
    $ 62.21万
  • 项目类别:
Lipid Deposition in the Right Ventricle in Pulmonary Arterial Hypertension
肺动脉高压右心室脂质沉积
  • 批准号:
    9474720
  • 财政年份:
    2015
  • 资助金额:
    $ 62.21万
  • 项目类别:
A molecular phenotype of combined pulmonary hypertension
合并性肺动脉高压的分子表型
  • 批准号:
    8796005
  • 财政年份:
    2014
  • 资助金额:
    $ 62.21万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.21万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.21万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 62.21万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.21万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 62.21万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.21万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.21万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.21万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 62.21万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 62.21万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了